FDA, EMA Accept Lusutrombopag Submissions, Priority Status Given in US: Shionogi

Shionogi said on February 27 that US and European regulators have accepted its submissions for the thrombocytopenia treatment lusutrombopag, with the FDA granting a priority status, setting its Prescription Drug User Fee Act (PDUFA) action date for August 26, 2018...read more